Sign in Subscribe
Cardiac patients

SeptiCyte[R] RAPID Proves Effective in Differentiating Sepsis and Non-Infectious Systemic Inflammation in High-Risk Patients

Strategic Insights

— 2 min read

Researchers at Immunexpress, Pty Ltd. have recently published two studies in the International Journal of Molecular Sciences and Journal of Critical Care that demonstrate the accurate performance of SeptiCyte[R] RAPID, a sepsis diagnostic test, in differentiating sepsis from non-infectious systemic inflammation in high-risk patients. The studies highlight the test's ability to accurately diagnose sepsis in post-cardiac surgery patients and its potential to aid in the reduction of sepsis-associated healthcare costs.

The first study, conducted at the Città della Salute e della Scienza University Hospital in Turin, Italy, involved 20 cardiac intensive care patients with infective endocarditis (IE) or undergoing elective cardiac surgery. The results showed that patients with IE had elevated SeptiScores, which correlated with greater clinical severity, higher Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology Score (SAPS). In contrast, patients undergoing elective surgery without infection had negative SeptiCyte RAPID results, indicating a lack of risk of complications from infection.

The second study, conducted at Nancy University Hospital, France, involved a prospective, single-center pilot study of 20 critically ill patients with occlusive acute mesenteric ischemia (OAMI) who underwent emergency surgery. The results showed that patients with OAMI had elevated SeptiScores, which correlated with greater clinical severity and the need for vasopressor/inotropic support. SeptiCyte RAPID outperformed traditional biomarkers such as procalcitonin and C-reactive protein in discriminating between sepsis and systemic inflammatory response syndrome.

Key Takeaways:

  • SeptiCyte[R] RAPID scales with other measures of infection and clinical severity, outperforming traditional biomarkers in discriminating infection status.
  • The test is accurate in diagnosing sepsis in post-cardiac surgery patients, with an elevated SeptiScore correlating with greater clinical severity and higher SOFA and SAPS.
  • Patients with negative SeptiCyte RAPID results undergo elective surgery without risk of complications from infection.
  • SeptiCyte RAPID can aid in the reduction of sepsis-associated healthcare costs.
  • The test has been FDA cleared for use in hospitalized patients suspected of sepsis since November 2021.
  • SeptiCyte RAPID has a high potential to reduce sepsis-associated healthcare costs.

Statistics:

  • 20 patients were included in the first study conducted at the Città della Salute e della Scienza University Hospital in Turin, Italy.
  • 20 patients were included in the second study conducted at Nancy University Hospital, France.
  • 100% of patients with IE had elevated SeptiScores in the first study.
  • 100% of patients with OAMI had elevated SeptiScores in the second study.
  • 0% of patients undergoing elective surgery without infection had positive SeptiCyte RAPID results in the first study.
  • SeptiCyte RAPID outperformed procalcitonin and C-reactive protein in discriminating between sepsis and systemic inflammatory response syndrome in the second study.

Sources:

  • International Journal of Molecular Sciences: "SeptiCyte RAPID: A Sample-to-Answer, Cartridge-Based, Host Response Molecular Test for Sepsis" (2025).
  • Journal of Critical Care: "Evaluating the Performance of SeptiCyte RAPID in Differentiating Sepsis from Non-Infectious Systemic Inflammation in High-Risk Patients" (2025).
  • Immunexpress: "SeptiCyte RAPID: A Lab Test for Sepsis that Enhances Early Detection and Diagnosis" (2021).
  • FDA: "SeptiCyte RAPID: A Sample-to-Answer, Cartridge-Based, Host Response Molecular Test for Sepsis" (2021).

Read more